연구성과로 돌아가기
2023 연구자 정보 (30 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Morsali, Ali (Morsali, A) |
Tarbiat Modares Univ, Fac Basic Sci, Dept Chem, Tehran, Iran |
ABL-3238-2022 Morsali, Ali |
|
[JCR상위 1.1] Metal-organic frameworks and metal-organic framework-derived materials for denitrogenation of liquid fuel via adsorption and catalysis | SCIE | 1.1 | CHEMISTRY, INORGANIC & NUCLEAR | sung@knu.ac.kr; | ||
|
Nam, E. (Nam, E) |
Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea |
|
|
[JCR상위 1.1] CHEMOKINE RECEPTOR CXCR7 CONTRIBUTE TO THE INFLAMMATORY REACTION OF ARTICULAR CHONDROCYTE | SCIE | 1.1 | ORTHOPEDICS;RHEUMATOLOGY | |||
|
Niikura, N. (Niikura, N) |
Tokai Univ, Breast Oncol, Sch Med, Isehara, Kanagawa, Japan |
|
|
[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) | SCIE | 1.1 | ONCOLOGY | |||
|
Niikura, Naoki (Niikura, N) |
Tokai Univ, Hiratsuka, Kanagawa, Japan |
|
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 [JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 |
SCIE | 1.1 | ONCOLOGY | |||
|
Nishijima, Soichiro (Nishijima, S) |
Daiichi Sankyo Co Ltd, Tokyo, Japan |
KVA-8556-2024 Nishijima, Soichiro |
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 | SCIE | 1.1 | ONCOLOGY | |||
|
Nishiyama, Yuji (Nishiyama, Y) |
Daiichi Sankyo Co Ltd, Tokyo, Japan |
|
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 | SCIE | 1.1 | ONCOLOGY | |||
|
Oh, H-J. (Oh, HJ) |
Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, Hwasun, South Korea Chonnam Natl Univ, Hwasun Hosp, Gwangju, Hwasun, South Korea |
|
|
[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach | SCIE | 1.1 | ONCOLOGY | |||
|
Oh, S. C. (Oh, SC) |
Korea Univ, Dept Internal Med, Seoul, South Korea Korea Univ, Oncol, Seoul, South Korea |
|
|
[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis [JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 |
SCIE | 1.1 | ONCOLOGY | |||
|
Ozaka, M. (Ozaka, M) |
Canc Inst Hosp JFCR, Dept Gastroenterol, Koto Ku, Tokyo, Japan |
|
|
[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | SCIE | 1.1 | ONCOLOGY | |||
|
Park, D. (Park, D) |
Ulsan Univ Hosp, Ulsan, South Korea Pusan Natl Univ Hosp, Dept Radiat Oncol, Busan, South Korea |
|
|
[JCR상위 1.1] ENHANCING OXIDATIVE PHOSPHORYLATION THROUGH INHIBITION OF PDK2 ALLEVIATES CARTILAGE DEGRADATION IN A SURGICAL MODEL OF OSTEOARTHRITIS [JCR상위 9.6] Albumin-Bilirubin (ALBI) score predicts hepatotoxicity after stereotactic ablative radiation therapy |
SCIE | 1.1 |
ORTHOPEDICS;RHEUMATOLOGY ONCOLOGY;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING |
|||
|
Park, H. -R. (Park, HR) |
Daegu Fatima Hosp, Fatima Res Inst, Daegu, South Korea |
|
|
[JCR상위 1.1] CHEMOKINE RECEPTOR CXCR7 CONTRIBUTE TO THE INFLAMMATORY REACTION OF ARTICULAR CHONDROCYTE | SCIE | 1.1 | ORTHOPEDICS;RHEUMATOLOGY | |||
|
Park, Hyun Soo (Park, HS) |
Dongguk Univ, Ilsan Hosp, Goyang, Kyonggi Do, South Korea |
|
|
[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus | SCIE | 1.1 | OBSTETRICS & GYNECOLOGY | |||
|
Park, J-Y. (Park, JY) |
Univ Ulsan, Dept Obstet & Gynecol, Asan Med Ctr, Seoul, South Korea |
IQU-2241-2023 Park, Junsu |
|
[JCR상위 1.1] A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | SCIE | 1.1 | ONCOLOGY | |||
|
Park, J. O. (Park, JO) |
Sungkyunkwan Univ, Samsung Med Ctr SMC, Sch Med, Oncol, Seoul, South Korea |
IQU-2241-2023 Park, Junsu |
|
[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | SCIE | 1.1 | ONCOLOGY | |||
|
Park, S-Y. (Park, SY) |
NCC Natl Canc Ctr, Gynecol Canc Ctr, Goyang Si, South Korea |
|
|
[JCR상위 1.1] A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | SCIE | 1.1 | ONCOLOGY |
페이지 이동: